Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160953 | 0.89 | IGF1R (0.43) | DGAT2UTS2R | |
| SCHEMBL14341049 | 0.86 | EZH2 (0.41) | KDRHPGDRAB9ASMN1; SMN2DGAT2 | |
| SCHEMBL14341052 | 0.86 | HTR4 (0.44) | UTS2RHTR4HTR1A | |
| SCHEMBL220979 | 0.86 | KMT2A (0.51) | — | |
| SCHEMBL6580849 | 0.85 | DRD4 (0.53) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6787079 | 0.84 | DRD4 (0.52) | SMN1; SMN2 | |
| SCHEMBL6582454 | 0.84 | EZH2 (0.39) | HPGDRAB9ASMN1; SMN2DGAT2MAPT | |
| SCHEMBL6580730 | 0.82 | TSHR (0.47) | RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14341048 | 0.82 | MAPT (0.35) | KDRHPGDRAB9ASMN1; SMN2DGAT2 | |
| SCHEMBL14354803 | 0.80 | TAS1R3 (0.52) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | claimed |
| EP-1753420-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105078-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | IDO1, IDO2, INMT | KDR 3933/4885PTK2 3364/4885SMYD3 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.